Research article · 14 Apr 2026
Research articlePublished 25 Aug 2023
Efficacy of Ceftolozane/Tazobactam in Infections with Multidrug-Resistant Gram-Negative Bacteria: A Preliminary Clinical Experience in a Highly Endemic Hospital
1Infectious Diseases Clinic, Azienda Ospedaliero University Delle Marche, Ancona, Italy; 2Department of Biomedical Sciences and Public Health, Polytechnic University of Marche Medical School, Ancona, Italy; 3Hospital Pharmacy, Azienda Ospedaliero University Delle Marche, Ancona, Italy; 4Anesthesia, Transplant and Surgical Intensive Care Unit, Azienda Ospedaliero University delle Marche, Ancona, Italy; 5Clinic of Anesthesia and General Resuscitation, Respiratory and Major Trauma, Azienda Ospedaliero University delle Marche Ancona, Italy
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Introduction: Ceftolozane/Tazobactam is a new cephalosporin/beta-lactams inhibitor combination proven to be a drug with efficacy against urinary tract infections, abdominal infections and nosocomial ventilator-associated pneumonia, supported by multi-resistant Gram-negative bacteria. Methods: This retrospective study considerated a cohort of 85 patients (≥ 18 years ), with a Gram-negative infection diagnosed between October 2017 and December 2020, treated with at least 72 hours of C/T therapy. The aim was to evaluate the efficacy, tolerability and to analyze any factors associated with a negative outcome. Results: The clinical success achieved in patients treated with ceftolozane/tazobactam in this coorte was 59%. Risk factors independently associated with mortality were neutropenia (p=0.02) and ICU stay (p=0.009). High mortality in ICU is related to complexity of patients with multiple devices and concomitant infections that needed combination of antibiotic therapy. Conclusion: Ceftolozano/tazobactam represents a therapy of choice in infections by Gram-MDR bacteria, also in that which multiple comorbidity and long hospital stay.
Subjects
Infectious DiseasesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Infectious Diseases & Therapy.
Research article · 5 May 2025
The Ultimate Cure for the COVID Syndemic
Mini review · 29 Apr 2025
COVID-19 Systematic Mini-Review as of April 2025
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Infectious Diseases & Therapy
- SubjectInfectious Diseases
- BylineArticles whose byline prints “Lucia Brescini”
- BylineArticles whose byline prints “Sara Mazzanti”
- BylineArticles whose byline prints “Luca Battistelli”
- BylineArticles whose byline prints “Gianluca Morroni”
- BylineArticles whose byline prints “Francesco Pallotta”
- BylineArticles whose byline prints “Bianca Candelaresi”
- BylineArticles whose byline prints “Silvia Olivieri”
- BylineArticles whose byline prints “Francesco Ginevri”